Europe's STOXX 600 fell on Friday, dragged by technology and healthcare stocks, keeping the index on track for its fourth ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

Sanofi India net profit down 46% in quarter ended September 30: Our Bureau, New Delhi Friday, November 8, 2024, 11:35 Hrs [IST] Sanofi India has registered 46 per cent decline in ...

Opella is Sanofi’s consumer healthcare business unit focusing on over-the-counter medicines, vitamins, minerals, and supplements and includes brands such as Allegra, Doliprane, and Dulcolax.

French pharma giant Sanofi is selling off its consumer healthcare business Opella ... of over-the-counter medicines and dietary supplements and includes well-known brands like Allegra (fexofenadine) ...

On our radar 2024 BASF readies a massive restructuring Sanofi ... its consumer health business, Opella, to the US private equity firm Clayton, Dubilier & Rice (CD&R). Opella, which houses brands ...

Sanofi Consumer Health Care India Ltd, the pharmaceutical company that makes Combiflam among other consumer drugs, announced to sell 26% of its equity shares to Opal Bidco SAS along with U.S ...

The drugmaker this week raised its annual profit forecast when announcing exclusive negotiations with US buyout firm Clayton Dubilier & Rice for the sale of its consumer health unit. Chief executive ...

Sanofi saw revenues for its consumer health arm, Opella, grow 7.9%. Earlier this week, Sanofi confirmed it had entered exclusive negotiations with U.S. private equity firm Clayton, Dubilier & Rice ...

The French government has warned the United States investment company buying the consumer healthcare division of drugmaker ...